The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
MrR, for info, it wasn't lifted, it is MF's article.
'10 stocks we like better than POINT Biopharma Global Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.'
What intrigues me about the (apparent) huge disparity between buys/sells, is the amount of 'stock' that is readily available. It seems that there is a large amount of free shares circulating, but where from.......unless there is another large background 'short', or someone has unloaded a significant holding (Medusa directors?). Or maybe the trading range is so tight the algo can't call a trade correctly. I have noticed in very recent times there have been a few occasions the same has happened.
For info I use iweb. Because these are otc shares & not listed on a major Exchange (in US) they are unable to transact on my behalf.
Amongst several others I found Schwab's appraisal of OTCs useful, & discouraging. Good luck ACUT holders.
https://www.schwab.com/stocks/understand-stocks/otc-stock
Quote contained in this article:
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-advanced-soft-tissue-sarcoma
As I understand it, isn't the current market size for these drugs $1bn/$2.3bn. If the pre/CISION platform improves the tolerated dose by, say, 5 times (think AS mentioned 20x FOR AVA6000 in last presentation), wouldn't that create the potential for a much larger market for both drugs?
If any of the TP correspondence is true, surely it's a matter (of concern) for Avacta, & the whole diagnostics industry. BlackCat ought to forward the whole lot to the Times/Telegraph/Mail, the various MPs, probably Javid et al.
It's more than a disgrace.......if true.
Marik, Trouble is we all know about manyana. Most of us wait in silent anticipation/expectation/hope as we believe in the mid/long term prospects of the Company. Think we are all frustrated, shareholders & employees alike, so, when contributors regularly forecast 'tomorrow' or 'this/next week' they raise their own credibilty stakes, & on a bb such as this, invite ridicule.
BBN was a strong Avacta advocate & an occasional poster. He is also a Twitter contributor, but he seems to have gone pretty quiet on the Company. May be he believes it will be the rns(s) that will provide the news we all await.
No one has/should have the 'inside track'; insider trading comes to mind. It's just a matter of research, follow the clues (personnel engagements etc), the variety of research papers that are printed (kindly shared on here), the partnerships that are announced & a few other strands.
I think Avacta will be succesful, but a number of contributors bombard this board with repetitive opinion (positive & negative) but very few facts, except those that we already know of. If the releases & presentations are to be believed, we have a good idea of potential here.
Patience is a virtue (but bad for the heart).
Thanks vrmnd & poirot, makes interesting reading. Wonder if AS has political ambitions?!
For info, a link to Reaction's BoD & Advisory Board https://reaction.life/about/
It was diagnostic. My own opinion was that they could not find any development partners, so it faded into the background. https://avacta.com/avacta-rapidly-generates-affimer-binders-zika-virus-diagnostics/
However, now they have developed a diagnostic, zika, & many other such viruses, will be on the agenda.
Ophidian what puzzles me about Medusa is tech transfer. At different times Avacta have alluded to BBI, ABDX, & GAD, but never Medusa. Surely, if they are to be a source of production we (the shareholders) would have been informed by rns that tt had commenced.
"Following the identification of subsurface #helium, our #HE1 CEO David Minchin is on route to #Tanzania to support the ongoing drilling operation"
is the tweet, which (to me) suggests this not a scheduled visit. Be surprised if bad news; why a tweet if it was? Think the latest Hannam appraisal is the key.
ndn yr 20:47. There is nothing about avacta to debate, unless there are moral questions around it's science. One either takes a (tentative) positive view on the path the company's on, or doesn't. Debating will not change anything about avacta, but it will cause friction on this bb. The only things that matter about any investment are facts & opportunities (open to it). We get very little in the way of fact on this board.